Tourmaline Bio Inc (TRML) Stock Price, Quote & News

Company Profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid e...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 481 9832

Website: www.tourmalinebio.com

Address:

27 West 24th Street, Suite 702, New York, United States

TwongStocks May. 20 at 6:25 PM

$TRML Nice recovery

0 · Reply

_www_larval_com_ May. 20 at 5:32 PM

$TRML has reverted 3% higher to -6% (~1Mv) in the last few minutes, 06/20 options, follow for more volatility.

0 · Reply

FractionalShareWhale May. 20 at 4:42 PM

$TRML this is down on positive news?

0 · Reply

OpenOutcrier May. 20 at 12:25 PM

$TRML (-3.8% pre) Tourmaline Bio stock slips after trial data https://ooc.bz/l/65360

0 · Reply

Thestocktraderhubzee May. 20 at 11:34 AM

$TRML Tourmaline Bio Announces Topline Results From Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug In Patients with Elevated High-Sensitivity C-reactive Protein And Chronic Kidney Disease

0 · Reply

TwongStocks May. 20 at 11:33 AM

$TRML Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial https://www.globenewswire.com/news-release/2025/05/20/3084742/0/en/Tourmaline-Bio-Announces-Positive-Topline-Results-from-the-Ongoing-Phase-2-TRANQUILITY-Trial-Evaluating-Pacibekitug-in-Patients-with-Elevated-High-Sensitivity-C-reactive-Protein-an.html • Conference call at 8:30am ET

0 · Reply

DonCorleone77 May. 20 at 11:33 AM

$TRML Tourmaline Bio announces results from ongoing Phase 2 TRANQUILITY trial Tourmaline Bio announced positive topline results from its ongoing Phase 2 TRANQUILITY trial evaluating quarterly and monthly subcutaneous dosing of pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP), a biomarker associated with elevated cardiovascular risk, and chronic kidney disease. The TRANQUILITY trial is the starting point of Tourmaline's clinical development program for pacibekitug for the potential treatment of atherosclerotic cardiovascular disease and other cardiovascular diseases. Tourmaline continues to make progress in advancing the clinical development strategy for pacibekitug in cardiovascular inflammation and assessing potential Phase 3 trial designs in patients with ASCVD. Additionally, Tourmaline plans to initiate a Phase 2 proof-of-concept trial in patients with abdominal aortic aneurysm in the second half of 2025.

0 · Reply

TwongStocks May. 19 at 8:15 PM

$TRML Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 https://www.globenewswire.com/news-release/2025/05/19/3084404/0/en/Tourmaline-Bio-to-Present-Topline-Results-from-the-Ongoing-Phase-2-TRANQUILITY-Trial-of-Pacibekitug-on-May-20-2025.html Conference call May 20 at 8:30am

0 · Reply

JarvisFlow May. 5 at 11:30 AM

HC Wainwright & Co. has updated their rating for Tourmaline Bio ( $TRML ) to Buy with a price target of 50.

0 · Reply

Rage_Against_The_Machine May. 2 at 11:53 AM

$TRML reports Q1 2025 results with $275.3M cash (runway into 2027) as TRANQUILITY Phase 2 data looms in Q2. R&D spend up 78% YoY to $20.3M shows aggressive trial push. Make-or-break moment: success here could position pacibekitug as Phase 3-ready in cardiovascular disease. High stakes, clean balance sheet. https://www.sec.gov/Archives/edgar/data/1827506/000182750625000058/trml-20250502.htm

1 · Reply

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 19, 2025, 4:05 PM EDT - 5 weeks ago

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 2, 2025, 7:30 AM EDT - 7 weeks ago

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 13, 2025, 7:30 AM EDT - 3 months ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 7:15 AM EST - 4 months ago

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Jan 10, 2025, 7:30 AM EST - 5 months ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Dec 10, 2024, 8:30 AM EST - 7 months ago

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Nov 14, 2024, 7:30 AM EST - 7 months ago

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Nov 7, 2024, 7:30 AM EST - 8 months ago

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 31, 2024, 7:30 AM EDT - 8 months ago

Tourmaline Bio to Present at Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 9 months ago

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

Oct 13, 2024, 10:29 AM EDT - 9 months ago

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Oct 11, 2024, 7:30 AM EDT - 9 months ago

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Oct 8, 2024, 7:30 AM EDT - 9 months ago

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

Aug 8, 2024, 7:30 AM EDT - 11 months ago

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 4:30 PM EDT - 11 months ago

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Jun 27, 2024, 8:05 AM EDT - 1 year ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

May 23, 2024, 7:10 AM EDT - 1 year ago

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

May 13, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 1, 2024, 8:00 AM EST - 1 year ago

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 29, 2024, 4:01 PM EST - 1 year ago

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jan 25, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Jan 24, 2024, 4:05 PM EST - 1 year ago

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Dec 15, 2023, 4:00 PM EST - 1 year ago

Tourmaline Bio added to the NASDAQ Biotechnology Index

Dec 14, 2023, 7:30 AM EST - 1 year ago

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

Nov 1, 2023, 2:09 PM EDT - 1 year ago

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6

Oct 19, 2023, 5:37 PM EDT - 1 year ago

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Oct 17, 2023, 5:47 PM EDT - 1 year ago

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Oct 6, 2023, 5:09 PM EDT - 1 year ago

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Oct 4, 2023, 8:30 AM EDT - 1 year ago

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

Sep 28, 2023, 2:47 PM EDT - 1 year ago

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

Jun 22, 2023, 7:30 AM EDT - 2 years ago

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

May 26, 2023, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Leadership Transition

Feb 16, 2023, 7:00 AM EST - 2 years ago

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Nov 22, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

Nov 10, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update

Nov 7, 2022, 7:00 AM EST - 2 years ago

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Oct 20, 2022, 8:24 AM EDT - 2 years ago

Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial

Oct 20, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

Oct 17, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Upcoming Presentations at American Society of Nephrology Annual Meeting

Oct 4, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa

Sep 21, 2022, 7:00 AM EDT - 2 years ago

Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Talaris Therapeutics to Participate in Two Upcoming Investor Conferences

Aug 29, 2022, 7:59 AM EDT - 3 years ago

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Aug 15, 2022, 7:00 AM EDT - 3 years ago

Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

Jun 30, 2022, 7:00 AM EDT - 3 years ago

Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

TwongStocks May. 20 at 6:25 PM

$TRML Nice recovery

0 · Reply

_www_larval_com_ May. 20 at 5:32 PM

$TRML has reverted 3% higher to -6% (~1Mv) in the last few minutes, 06/20 options, follow for more volatility.

0 · Reply

FractionalShareWhale May. 20 at 4:42 PM

$TRML this is down on positive news?

0 · Reply

OpenOutcrier May. 20 at 12:25 PM

$TRML (-3.8% pre) Tourmaline Bio stock slips after trial data https://ooc.bz/l/65360

0 · Reply

Thestocktraderhubzee May. 20 at 11:34 AM

$TRML Tourmaline Bio Announces Topline Results From Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug In Patients with Elevated High-Sensitivity C-reactive Protein And Chronic Kidney Disease

0 · Reply

TwongStocks May. 20 at 11:33 AM

0 · Reply

DonCorleone77 May. 20 at 11:33 AM

0 · Reply

TwongStocks May. 19 at 8:15 PM

0 · Reply

JarvisFlow May. 5 at 11:30 AM

HC Wainwright & Co. has updated their rating for Tourmaline Bio ( $TRML ) to Buy with a price target of 50.

0 · Reply

Rage_Against_The_Machine May. 2 at 11:53 AM

1 · Reply

DonCorleone77 May. 2 at 11:45 AM

$TRML Tourmaline Bio reports Q1 EPS (89c), consensus (94c) "We continue to see growing evidence and enthusiasm for the potential of addressing IL-6-driven cardiovascular inflammation through our discussions with cardiovascular disease experts, attendance at major medical conferences, and review of constantly emerging scientific literature," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "We look forward to the expected presentation of topline data from our Phase 2 TRANQUILITY trial of pacibekitug later in the second quarter. This readout has the potential to advance pacibekitug into the next stage of development within atherosclerotic cardiovascular disease, abdominal aortic aneurysm, and potentially other cardiovascular diseases."

0 · Reply

JarvisFlow Apr. 23 at 10:30 AM

Chardan Capital has updated their rating for Tourmaline Bio ( $TRML ) to Buy with a price target of 70.

0 · Reply

QuantInsider Apr. 2 at 4:33 PM

Did anyone else catch that wild jump in options volume for $TRML? We're talking 4.7 times the usual action here—definitely feels like something's brewing! Whether it’s a big news drop or just some traders getting a bit too excited, it's got my attention. I’m curious if this is the calm before a storm or just another case of overzealous buying. What’s everyone thinking?

0 · Reply

Whytheykeepmutingme Mar. 26 at 4:08 PM

$DLHC $GRO $NBR $TRML nice

0 · Reply

JarvisFlow Mar. 14 at 1:49 PM

Wedbush updates rating for Tourmaline Bio ( $TRML ) to Outperform, target set at 42 → 43.

0 · Reply

JarvisFlow Mar. 14 at 11:00 AM

HC Wainwright & Co. updates rating for Tourmaline Bio ( $TRML ) to Buy, target set at 49 → 50.

0 · Reply

jParkz Mar. 13 at 7:30 PM

News Article $TRML Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights https://marketwirenews.com/news-releases/tourmaline-bio-reports-fourth-quarter-and-full-year--5912656889331087.html $TRML

0 · Reply

d_risk Mar. 13 at 4:24 PM

$TRML - Tourmaline Bio Inc. Common Stock - 10K - Updated Risk Factors TRML's 2025 10-K Risk Factors highlight a shift from TOUR006 to pacibekitug, with new risks in clinical success, regulatory approval, manufacturing disruptions, and financial dependencies. Expanded focus on cybersecurity, legal compliance, and intellectual property challenges, alongside potential impacts from healthcare reforms and economic volatility. #Risk https://d-risk.ai/TRML/10-K/2025-03-13

0 · Reply

DonCorleone77 Mar. 13 at 11:42 AM

$TRML Tourmaline Bio sees cash runway into 2H27 Cash, cash equivalents and investments were $294.9 million as of December 31, 2024, as compared to $203.0 million as of December 31, 2023. Tourmaline anticipates that its current cash, cash equivalents, and investments will provide cash runway into the second half of 2027, funding its operations through key pacibekitug data readouts in cardiovascular inflammation and TED as well as other pacibekitug development activities.

1 · Reply

DonCorleone77 Mar. 13 at 11:41 AM

$TRML Tourmaline Bio reports Q4 EPS (86c), consensus (87c) "2024 was an important year of execution as it relates to our clinical development programs in cardiovascular inflammation and thyroid eye disease," said Sandeep Kulkarni, CEO. "We are now transitioning into a potentially transformative year of data in 2025, leading off with topline data from our Phase 2 TRANQUILITY trial expected in the second quarter. Complemented by our strong balance sheet and with the support of our world-class team, we look forward to sharing our first data readouts this year and making further progress towards realizing the enormous standard-of-care changing potential of pacibekitug."

0 · Reply

Ikea07 Mar. 8 at 5:06 PM

$TRML

0 · Reply

JarvisFlow Mar. 6 at 2:08 PM

Wedbush has updated their rating for Tourmaline Bio ( $TRML ) to Outperform with a price target of 42.

0 · Reply

Market Cap	437.16M
Revenue (ttm)	0.00
Net Income (ttm)	-73.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	176,600
Avg Vol	322,974
Day's Range	N/A - N/A
Shares Out	25.69M
Stochastic %K	16%
Beta	2.05
Analysts	Strong Sell
Price Target	$55.70